| What it is | Topical Netarsudil (a Rho kinase inhibitor) administered after vitrectomy or vitrectomy with scleral buckle in phakic eyes (natural lens) for primary rhegmatogenous retinal detachment. | Topical Netarsudil administered postoperatively in pseudophakic eyes (intraocular lens implant) for primary rhegmatogenous retinal detachment repair. | Topical Netarsudil given after vitrectomy repair in phakic eyes with secondary detachment (from open globe trauma or advanced PVR). | Topical Netarsudil given postoperatively in pseudophakic eyes with secondary detachment (open globe trauma or advanced PVR). | Current care consists of standard surgical repair (vitrectomy with or without scleral buckle), postoperative monitoring, and follow-up, without the use of any adjunctive pharmacologic agent for PVR prevention. |
|---|
| Role in trial | Participants in this group receive Netarsudil after surgery for a primary rhegmatogenous detachment in a phakic eye. | Participants are assigned to get Netarsudil after surgery for a primary detachment in a pseudophakic eye. | Participants receive Netarsudil after surgery for detachment secondary to trauma or advanced PVR in a phakic eye. | Participants receive Netarsudil after surgery for detachment secondary to trauma or advanced PVR in a pseudophakic eye. | Current standard care involves surgical repair followed by monitoring and standard follow-up without adjunctive pharmacologic therapy for PVR prevention. |
|---|
| Primary use | Being studied to assess whether adjunctive topical Netarsudil after vitrectomy can reduce risk of proliferative vitreoretinopathy in phakic eyes with primary detachment. | Being studied for PVR prevention in pseudophakic eyes after primary detachment repair with vitrectomy. | Being evaluated for PVR prevention in phakic eyes undergoing surgery for secondary detachment due to trauma or advanced PVR. | Studied for reducing PVR risk after surgery for secondary detachment in pseudophakic eyes. | Standard care aims to achieve retinal reattachment and visual recovery, with prevention of PVR relying mainly on timely surgical intervention and monitoring; no established pharmacologic agent is routinely used. |
|---|
| How it is given/performed | Topical Netarsudil eye drops are administered after retinal detachment repair surgery in phakic eyes, as per the trial protocol. | Netarsudil eye drops are instilled postoperatively in pseudophakic eyes following vitrectomy for retinal detachment. | Netarsudil drops are given after vitrectomy surgery for phakic eyes with secondary detachment. | Netarsudil is delivered topically after surgery in pseudophakic eyes with secondary PVR-related detachment. | Patients receive vitrectomy-based surgical repair (with or without scleral buckle) and post-surgical monitoring; no adjunctive pharmacologic therapy is administered for PVR prevention. |
|---|
| Evidence status | Efficacy and safety of Netarsudil for PVR prevention after retinal detachment repair have not yet been established; current trial is an early-phase clinical study. | No established evidence for Netarsudil's effectiveness in PVR prevention after primary detachment repair in pseudophakic eyes; results pending. | Netarsudil's benefit for PVR prevention after surgery in phakic eyes with secondary detachment is unknown; evidence limited to ongoing trial. | No clinical evidence currently confirms Netarsudil's utility for PVR prevention in this setting; trial is in progress. | Observation and standard postoperative management remain the established care pathway due to lack of proven pharmacologic options for PVR prevention; recent reviews highlight absence of effective drug-based prophylaxis for PVR. |
|---|
| Important limitations | Risks of ocular surface irritation, corneal edema, and lack of long-term safety data for Netarsudil in this post-surgical population; benefit for PVR prevention is unproven and mechanism is investigational. | Potential for drug-related ocular side effects, uncertain long-term safety and efficacy for PVR prevention, and lack of established benefit in pseudophakic setting. | Potential for local ocular adverse effects; unknown impact on PVR risk reduction; applicability to trauma/advanced PVR populations requires further study. | Safety for this patient group and net preventive effect for PVR are not yet established; ocular adverse events possible. | Standard care leaves a significant, unaddressed risk of PVR recurrence; no pharmacologic means currently exists to reduce PVR risk. |
|---|